Please check your internet connection and try again.
# Piperacillin/Tazobactam (Zosyn)
## Overview
Piperacillin/tazobactam is a combination antibiotic consisting of piperacillin, a broad-spectrum penicillin antibiotic, and tazobactam, a beta-lactamase inhibitor. It is effective against many Gram-positive, Gram-negative, and anaerobic bacteria.
## Primary Indications
* Complicated intra-abdominal infections
* Complicated skin and skin structure infections
* Community-acquired pneumonia
* Hospital-acquired pneumonia (including ventilator-associated pneumonia)
* Empirical treatment of febrile neutropenia
## Adult Dosing
* **Standard Dose:** 3.375 grams (piperacillin 3 g / tazobactam 0.375 g) intravenously every 6 hours.
* **Higher Dose:** 4.5 grams (piperacillin 4 g / tazobactam 0.5 g) intravenously every 6 or 8 hours.
* Dosing frequency and duration depend on the severity and type of infection, pathogen susceptibility, and clinical response.
* For severe infections, higher doses (e.g., 4.5 g q6h) are often preferred.
* Some guidelines suggest extended or continuous infusions for severe infections to optimize pharmacokinetic/pharmacodynamic targets. Local protocols should be consulted.
## Pediatric Dosing
* **For patients ≥ 2 months of age:**
* **Intra-abdominal infections:** 100 mg piperacillin/kg/day divided into doses every 6 hours.
* **Other infections (skin/soft tissue, pneumonia, febrile neutropenia):** 200-300 mg piperacillin/kg/day divided into doses every 6 or 8 hours.
* **Maximum dose:** 4.5 grams per dose.
* **Note:** Dosing should not exceed the adult maximum dose. Actual tazobactam dose is 1/8th of the piperacillin dose. Always consult institutional guidelines for specific pediatric dosing.
## Dose Adjustments
* **Renal Impairment (CrCl < 20 mL/min):** Reduce dose frequency or amount. Consult prescribing information for specific recommendations.
* **Hepatic Impairment:** No dose adjustment necessary.
## Contraindications
* Hypersensitivity to piperacillin, tazobactam, other penicillin antibiotics, or any component of the formulation.
* History of allergic reaction to cephalosporins or other beta-lactams.
## Adverse Effects
* **Common:** Diarrhea, nausea, vomiting, rash, headache, insomnia, constipation, abdominal pain, elevated liver enzymes.
* **Serious:** *Clostridioides difficile*-associated diarrhea, hypersensitivity reactions (including anaphylaxis), seizures, neutropenia, thrombocytopenia, interstitial nephritis.
## Key Drug Interactions
* **Probenecid:** May increase and prolong piperacillin/tazobactam plasma concentrations.
* **Neuromuscular blocking agents (e.g., vecuronium):** Piperacillin may prolong the effect of vecuronium.
* **Warfarin:** May decrease the effect of warfarin. Monitor INR closely.
* **Methotrexate:** Piperacillin may decrease methotrexate clearance. Monitor methotrexate levels.
## Monitoring
* Renal function (especially in patients with pre-existing renal impairment or those receiving nephrotoxic agents).
* Liver function tests.
* Complete blood count (especially with prolonged therapy, monitor for neutropenia and thrombocytopenia).
* Signs and symptoms of hypersensitivity reactions.
* Signs and symptoms of *C. difficile*-associated diarrhea.
## Clinical Pearls
* Piperacillin/tazobactam is a broad-spectrum agent often used in empirical therapy for serious infections.
* Consider de-escalation to a narrower-spectrum agent once culture and susceptibility results are available.
* For patients with severe renal impairment, dose adjustment and/or increased dosing interval is crucial to avoid accumulation and potential toxicity.
* Extended or continuous infusions can improve efficacy by maintaining drug concentrations above the minimum inhibitory concentration (MIC) for longer periods, particularly important for organisms with lower susceptibility. Consult institutional protocols.
* The addition of tazobactam broadens the spectrum of activity to include many beta-lactamase producing organisms.
***
*This information is intended for healthcare professionals. Always consult the most current prescribing information and institutional guidelines before administering any medication.*
